Sapience Therapeutics
Clinical trials sponsored by Sapience Therapeutics, explained in plain language.
-
Can a new drug ST316 shrink Hard-to-Treat tumors?
Disease control OngoingThis trial tests an experimental drug called ST316, alone or with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The study focuses on tumors that may have abnormalities in a cell signaling pathway called WNT/β-catenin. The…
Phase: PHASE1 • Sponsor: Sapience Therapeutics • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New drug ST101 takes on Hard-to-Treat cancers
Disease control OngoingThis study tests an experimental drug called ST101 in people with advanced solid tumors that cannot be removed by surgery or have spread. The trial includes cancers like glioblastoma, melanoma, breast, and prostate cancer. It aims to find a safe dose and see if the drug can shrin…
Phase: PHASE1, PHASE2 • Sponsor: Sapience Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC